Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors.

B cells of chronic lymphocytic leukemia (B-CLL) are resistant to transduction with most currently available vector systems. Using an optimized adenovirus-free packaging system, recombinant adeno-associated virus (rAAV) vectors coding for the enhanced green fluorescent protein (AAV/EGFP) and CD40 ligand (AAV/CD40L) were packaged and highly purified resulting in genomic titers up to 3 x 10(11)/mL. Cells obtained from 24 patients with B-CLL were infected with AAV/EGFP or AAV/CD40L at a multiplicity of infection (MOI) of 100 resulting in transgene expression in up to 97% of cells as detected by flow cytometry 48 hours after infection. Viral transduction could be specifically blocked by heparin. Transduction with AAV/CD40L resulted in up-regulation of the costimulatory molecule CD80 not only on infected CLL cells but also on noninfected bystander leukemia B cells, whereas this effect induced specific proliferation of HLA-matched allogeneic T cells. Vaccination strategies for patients with B-CLL using leukemia cells infected ex vivo by rAAV vectors now seems possible in the near future.

[1]  D. McCarty,et al.  Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis , 2001, Gene Therapy.

[2]  M. Hallek,et al.  Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors , 2001, Gene Therapy.

[3]  M Chilosi,et al.  Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[4]  R. Samulski,et al.  Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  L. Rassenti,et al.  CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. , 2000, Blood.

[6]  J. Gribben,et al.  Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies , 2000, Nature Medicine.

[7]  K. Anderson,et al.  CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. , 2000, Blood.

[8]  Jody A. Vandergriff,et al.  Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38− subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV , 2000, Gene Therapy.

[9]  Arun Srivastava,et al.  Impaired Intracellular Trafficking of Adeno-Associated Virus Type 2 Vectors Limits Efficient Transduction of Murine Fibroblasts , 2000, Journal of Virology.

[10]  J. Qiu,et al.  Integrin αVβ5 Is Not Involved in Adeno-Associated Virus Type 2 (AAV2) Infection , 1999 .

[11]  Y. Hanazono,et al.  In vivo marking of rhesus monkey lymphocytes by adeno-associated viral vectors: direct comparison with retroviral vectors. , 1999, Blood.

[12]  G. Deléage,et al.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.

[13]  P. Dijkhuizen,et al.  Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. , 1999, Human gene therapy.

[14]  W. Hahn,et al.  The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.

[15]  B. Byrne,et al.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.

[16]  R. Buhmann,et al.  CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. , 1999, Blood.

[17]  J. Qiu,et al.  Integrin alphaVbeta5 is not involved in adeno-associated virus type 2 (AAV2) infection. , 1999, Virology.

[18]  Keyun Qing,et al.  Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 , 1999, Nature Medicine.

[19]  R. Samulski,et al.  αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection , 1999, Nature Medicine.

[20]  G. Deléage,et al.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.

[21]  D. Grimm,et al.  Novel tools for production and purification of recombinant adenoassociated virus vectors. , 1998, Human gene therapy.

[22]  Arun Srivastava,et al.  Adeno-Associated Virus Type 2-Mediated Gene Transfer: Role of Epidermal Growth Factor Receptor Protein Tyrosine Kinase in Transgene Expression , 1998, Journal of Virology.

[23]  D. Schadendorf,et al.  Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. , 1998, Human gene therapy.

[24]  T. Kipps,et al.  Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. , 1998, The Journal of clinical investigation.

[25]  R. Samulski,et al.  Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.

[26]  S. Ponnazhagan,et al.  Adeno-Associated Virus Type 2-Mediated Gene Transfer: Correlation of Tyrosine Phosphorylation of the Cellular Single-Stranded D Sequence-Binding Protein with Transgene Expression in Human Cells In Vitro and Murine Tissues In Vivo , 1998, Journal of Virology.

[27]  R. Samulski,et al.  Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.

[28]  T. Kipps,et al.  Acquired CD40-ligand deficiency in chronic lymphocytic leukemia , 1997, Nature Medicine.

[29]  R. Buhmann,et al.  Gene transfer of costimulatory molecules B7–1 and B7–2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response , 1997, Gene Therapy.

[30]  S. Ponnazhagan,et al.  Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Kipps,et al.  Adenovirus vector infection of chronic lymphocytic leukemia B cells. , 1996, Blood.

[32]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[33]  R. Kotin,et al.  High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. , 1995, Human gene therapy.

[34]  D. Russell,et al.  DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Russell,et al.  DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors , 1994, Journal of virology.

[36]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  T. Kipps,et al.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.

[38]  A. Lanzavecchia,et al.  Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation , 1993, The Journal of experimental medicine.

[39]  Samulski,et al.  Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression , 1989, Journal of virology.

[40]  R. Samulski,et al.  A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication , 1987, Journal of virology.